The Cannabidiol and Marihuana Research Expansion Act
During the 116th Congress, Senators Feinstein and Grassley introduced the Cannabidiol and Marihuana Research Expansion Act, designed to remove barriers to researching cannabis and creates a pathway for cannabis-derived medications to be approved by the Food and Drug Administration (FDA), using strains of cannabis and cannabidiol (CBD) that are grown and produced by researchers. Senators Feinstein and Grassley reintroduced the bill during the 117th Congress on March 2, 2021, urging Congress to pass the legislation to better understand the health effects of cannabis and cannabis-derived products. absent more robust research, policymakers have little information or evidence upon which to base future decisions related to cannabis.
